

1 Photocatalytic Late-stage Functionalization of Dehydroalanine-derived 2 Peptides in Batch and Flow

3 Nikolaos Kaplaneris,^[a] Merve Akdeniz,^[a] Méritxell Fillols,^[a] Francesca Arrighi,^[a,b] Fabian
4 Raymenants,^[a] Gana Sanil,^[a,c] Daniel T. Gryko,^[c] and Timothy Noël*^[a]

5 ^[a] Flow Chemistry Group, Van't Hoff Institute for Molecular Sciences (HIMS), University of
6 Amsterdam, Science Park 904, 1098 XH, Amsterdam (The Netherlands)

7 ^[b] Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le Aldo
8 Moro 5, 00185, Rome (Italy)

9 ^[c] Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224,
10 Warsaw (Poland)

11 *Correspondence to: T.Noel@uva.nl.

12 ABSTRACT

13 Unnatural amino acids, and their synthesis via the late-stage functionalization (LSF) of
14 peptides, play a crucial role in areas such as drug design and discovery. Historically, the LSF of
15 biomolecules has predominantly utilized traditional synthetic methodologies that exploit
16 nucleophilic residues, such as cysteine, lysine or tyrosine. In this study, we present a
17 photocatalytic hydroarylation process targeting the electrophilic residue dehydroalanine (Dha).
18 This residue possesses an α,β -unsaturated moiety and can be combined with various
19 arylthianthrenium salts, both in batch and flow reactors. Notably, the flow setup proved
20 instrumental for efficient scale-up, paving the way for the synthesis of unnatural amino acids
21 and peptides in substantial quantities. Our photocatalytic approach, being inherently mild,
22 permits the diversification of peptides even when they contain sensitive functional groups. The

23 readily available arylthianthrenium salts facilitate the seamless integration of Dha-infused
24 peptides with a wide range of arenes, drug blueprints, and natural products, culminating in the
25 creation of unconventional phenylalanine derivatives. The synergistic effect of the high
26 functional group tolerance and the modular characteristic of the aryl electrophile enables
27 efficient peptide conjugation and ligation in both batch and flow conditions.

28 **Main article.**


29 Peptide and protein therapeutics are currently experiencing a significant breakthrough,
30 setting them on par with small molecules as potential drug candidates.^[1] Late-stage
31 functionalization (LSF) of biomolecules and drug scaffolds has proven to be a powerful strategy
32 for efficiently exploring the chemical landscape, eliminating the need for expensive and
33 resource-intensive de novo methodologies.^[2] Consequently, the site- and chemoselective LSF
34 of peptides has garnered substantial interest from both academic researchers and the
35 pharmaceutical industry.

36 Within this context, the incorporation of unnatural amino acids into peptides can
37 significantly modify their bioactivity and enhance proteolytic stability.^[3] For the LSF of
38 peptides to be effective, it necessitates highly selective and mild reaction conditions capable of
39 forging bonds with high precision amidst the complex array of functional groups inherent to
40 peptides. To overcome this challenge, a diverse array of synthetic strategies has been utilized,
41 encompassing classical condensations and (cyclo)additions,^[4] transition-metal catalysis,^[5] click
42 chemistry,^[6] photochemistry,^[7] and more recently electrochemistry.^[8] Notably, among the
43 proteinogenic amino acids, those with nucleophilic side chains have been most extensively
44 investigated for photochemical LSF.^[9] Key examples include cysteine,^[10] tryptophan,^[11]
45 methionine,^[12] and tyrosine.^[13]

46 In contrast, dehydroalanine (Dha) represents an electrophilic residue that, although not
47 proteinogenic, occurs naturally and is prevalent in a host of antimicrobial peptides.^[14] It

48 presents an alternative avenue for functionalization, as depicted in Figure 1a.^[15] The recent
49 advancement in photochemical LSF of Dha-enriched peptides^[16] has facilitated targeted and
50 chemoselective processes such as alkylation,^[17] fluoroalkylation,^[18] acylation,^[19] and to a more
51 limited degree, arylation.^[20] Prior arylation approaches typically demanded aryl bromides as
52 coupling agents, necessitating complex and laborious *de novo* synthesis to produce a variety of
53 functionalized partners. However, recent studies by the groups of Ritter,^[21] Procter,^[22] and
54 Alcarazo^[23] has highlighted the utility of arylsulfonium salts. These salts enable straightforward
55 preparation routes leading to intricate aryl electrophiles,^[24] which are instrumental for both
56 transition metal-catalyzed cross-coupling chemistry^[25] and photochemical applications.^[26]
57 Building on this, vinyl-sulfonium salts have recently been employed for various polar
58 transformations.^[27]

59 Therefore, we were intrigued by the prospect of developing a photocatalytic LSF
60 approach for Dha-containing peptides using the highly versatile and modular arylthianthrenium
61 salts, as illustrated in Figure 1b. This transformation was accomplished by the single electron
62 transfer (SET) reduction of these salts, which generates an exceptionally reactive aryl radical.
63 This radical readily adds to the α,β -unsaturated moiety within the Dha backbone. To guarantee
64 gentle reaction conditions and minimize reaction times—key factors for ensuring broad
65 functional group compatibility and scalability—we also devised a continuous-flow protocol.^[28]
66 Notably, our method facilitates the efficient ligation of peptides and their conjugation with
67 various drug scaffolds.



68

69 **Figure 1.** a) Dha diversification. b) Photocatalytic LSF of Dha-containing peptides with
70 arylthiantrinium salts.


71

72 Our initial efforts in achieving regioselective arylation of Dha-derivative **2** focused on the use
73 of arylthiantrinium salt **1** (For detailed optimization, see Supporting Information). We
74 employed DIPEA as the stoichiometric reductant and eosin Y as a photocatalyst, with the
75 reaction driven by visible light irradiation at a wavelength of 456 nm (Table 1). The reaction
76 proceeded efficiently (72% isolated yield) in a solvent mixture of MeCN:HFIP (7:1) at room
77 temperature over 4 hours (Table 1, Entry 1). Other protic or aprotic polar solvents failed to
78 provide satisfactory conversions (Table 1, Entries 2 and 3). It became evident that the choice of
79 solvent was critical; variations in the solvent system composition, containing different ratios
80 between MeCN and HFIP, resulted in decreased yields (Table 1, Entry 4). A control experiment
81 demonstrated the essential role of DIPEA (entry 5). Other potential reductants, including
82 various amines and dihydropyridines, were also tested but failed to effectively produce the
83 target product **3** (Table 1, Entries 6 and 7). Furthermore, we explored a range of photo-
84 organocatalysts and metal-based photocatalysts, which unfortunately led to less efficient
85 processes (Table 1, Entries 8 and 9). Gratifyingly, the synthesis of the unnatural amino acid **3**

86 could be smoothly performed in a continuous-flow photoreactor in a significantly reduced
87 reaction time ($t_R = 20$ min) with comparable efficiency (Table 1, Entry 10).

88 Building upon the established optimal conditions for the photocatalytic arylation of Dha
89 **2**, both in batch and flow (Table 1, Entries 1 and 10), we sought to evaluate the versatility and
90 scope of our method. Hereto, we applied various arylthianthrenium salts **4** to the established
91 protocol, as delineated in Scheme 1. Scaling up our model reaction using arylthianthrenium salt
92 **1** and Dha-derivative **2** via flow technology was successful, achieving a 71% isolated yield at
93 a 1.0 mmol scale under our standard conditions.

94 **Table 1.** Optimization of the photocatalytic arylation of the Dha-derivative **2** with
95 arylthianthrenium salt **1**.^[a]



96

Entry	Deviation from the standard conditions	Yield [%] ^[b]
1	None	72
2	MeOH/ <i>i</i> -PrOH/HFIP/DMF/DMSO as solvent	40/38/nd/nd/nd
3	MeCN as solvent	45
4	MeCN:HFIP (1:1)/(3:1)/(19:1) as solvent	36/63/49
5	without DIPEA	nd
6	TEA/TBA/DABCO/TEOA instead of DIPEA	37/29/nd/55
7	hantzsch ester (2.0 equiv) instead of DIPEA	23
8	eosin Y-Na ₂ /fluorescein/rhodamine B/Ru(bpy) ₃ Cl ₂ as photocatalyst	68/47/52/45
9	Ir(ppy) ₃ /10-phenylphenothiazine as photocatalyst	nd/10 ^[c]
10	under flow conditions $t_R = 20$ min	69

97
98 ^[a] Reaction conditions: **1** (0.20 mmol), **2** (1.0 mmol), eosin Y (5.0 mol%), DIPEA (1.0 mmol),
99 MeCN:HFIP (7:1, 4.0 mL), at room temperature, 456 nm for 4 h. ^[b] Yield of isolated product.


100 ^[c] Yield determined by ¹H-NMR spectroscopy using trichloroethylene as external standard.

101 HFIP: 1,1,1,3,3,3-hexafluoro-2-propanol, DMF: *N,N*-dimethylformamide, DMSO: dimethyl

102 sulfoxide, DIPEA: *N,N*-diisopropylethylamine, TEA: triethylamine, TBA: tributylamine,
103 DABCO: 1,4-diazabicyclo[2.2.2]octane, TEOA: 2-(bis(2-hydroxyethyl)amino)ethanol, bpy:
104 2,2'-bipyridine, ppy: 2-phenylpyridine.

105

106 We then extended our approach to include alkyl-substituted arylthianthrenium salts **4**, which
107 served as competent reaction partners into our protocol, yielding the anticipated products **7-12**
108 in good to excellent isolated yields. Notably, the synthesis of biaryl unnatural amino acids **13-**
109 **15** was achieved in excellent yields. These amino acids bear functional groups amenable to
110 subsequent synthetic manipulations, such as condensations and transition-metal catalyzed
111 cross-couplings. Impressively, the aryl iodide bond, typically sensitive to reduction under
112 photocatalytic conditions, proved to be compatible with our process. The method's adaptability
113 was further underscored by its application to heteroatom-containing arylthianthrenium salts **4**,
114 leading to an array of phenylalanine derivatives (**16-24**). The yields were moderate to excellent,
115 maintaining both high chemo- and regioselectivity. Additionally, our methodology
116 demonstrated its robust functional group tolerance by facilitating access to a diverse set of
117 heterocycle-containing amino acids. This collection of compounds included structures with
118 dihydrobenzofuran, benzodioxole, chromanone, xanthone, pyridine, carbazole, indoline, and
119 quinazoline-dione, showcasing the broad applicability and robustness of the synthetic strategy.
120 In addition, our methodology enabled the synthesis of diverse amino acid derivatives for peptide
121 synthesis, incorporating orthogonal protecting groups, requiring only minor adjustments to
122 reaction conditions. We evaluated acid-, base- and hydrogenation-labile protecting groups,
123 including *tert*-butyloxycarbonyl (Boc), fluorenylmethyloxycarbonyl (Fmoc), and
124 benzyloxycarbonyl (Cbz) resulting in the successful preparation of the desired building blocks
125 **33-35**.




126

127 **Scheme 1.** Synthesis of unnatural amino acids *via* radical addition to Dha derivative **5** using
 128 various arylthianthrenium salts. For further experimental details see the Supporting
 129 Information.

130


131 The streamlined and selective synthesis of arylthianthrenium salts prompted us to investigate
 132 their application with drug scaffolds and natural product derivatives, numbered as **36**, within
 133 our photocatalytic protocol, aiming to create distinctive conjugates as depicted in Scheme 2.

134 The process proved to be of high value, allowing for the seamless integration of a variety of
 135 drugs onto the Dha-backbone, yielding an array of novel amino acid/drug conjugates **38**. The
 136 mild conditions of our photocatalytic hydroarylation were evidenced by the complete
 137 preservation of vulnerable heterocyclic structures, such as those found in pyriproxen,
 138 bifonazole, boscalid, and benzbromarone. The successful incorporation of drug scaffolds onto
 139 amino acid backbones led us to extend our strategy to the chemical ligation of peptides. We
 140 utilized an arylthianthrenium salt derivative of phenylalanine under our standard conditions,
 141 which afforded the targeted unnatural dipeptide **47** with excellent chemo- and regioselectivity.
 142 Furthermore, we synthesized a series of conjugates employing continuous-flow conditions,
 143 achieving similar success even when scaling up the reactions, which underscores the
 144 practicality and scalability of our synthetic approach.



145
 146 **Scheme 2.** Synthesis of conjugated and ligated unnatural amino acids *via* radical addition to
 147 Dha derivative **2** using arylthianthrenium salts **37** derived from biologically active molecules
 148 **36**. For further experimental details see the Supporting Information.

149 We then advanced to the late-stage functionalization of more complex peptide structures **48**,
 150 applying our photocatalytic conditions detailed in Scheme 3. We were able to precisely and
 151 selectively functionalize a variety of di-,tri-, penta- and hexapeptides, decorating them with a
 152 multitude of functional groups derived from the aromatic core. Notably, peptides containing
 153 residues with sensitive functionalities like thioether, phenol, and indole groups were tolerated
 154 without any interference from photocatalytic single electron transfer (SET) processes or



155 **Scheme 3.** LSF of Dha-containing peptides **44** leading to conjugation and ligation. For further
 156

157 experimental details see the Supporting Information.

158 hydrogen atom transfer reactions, which typically present significant deleterious side pathways.
159 In addition, our protocol was not hindered by the position of the Dha residue in the peptide, as
160 the functionalization at *N*-, *C*-terminus as well as inside the peptide sequence was
161 accomplished. Furthermore, our methodology facilitated the rapid synthesis of a tripeptide **66**,
162 which showcased an atypical linkage, demonstrating the applicability of our ligation
163 techniques. This process also proved to be highly capable at integrating drug scaffolds with
164 peptides, further emphasizing the remarkable functional group compatibility of our system,
165 even within the intricate context of peptide conjugation

166 In conclusion, we have successfully developed a photocatalytic hydroarylation protocol that
167 efficiently targets the Dha-backbone utilizing versatile arylthianthrenium salts. This novel
168 strategy has demonstrated its versatility in synthesizing a diverse array of unnatural amino
169 acids, with the potential for straightforward scale-up under a continuous-flow regime. The
170 remarkable functional group tolerance of our methodology enables the preservation of delicate
171 chemical structures during synthesis, broadening the scope of compatible coupling partners.
172 Furthermore, the precise site- and chemoselectivity of this technique showcase its utility in the
173 modification of peptides bearing a variety of sensitive residues. Looking forward, this mild
174 photocatalytic approach is poised to impact the late-stage functionalization of complex peptides
175 and proteins, offering new avenues for biochemical research and therapeutic development.

176

177 **Acknowledgements**

178 We are grateful to have received generous funding from the European Union H2020 under the
179 call HORIZON-HLTH-2021-IND-07 (SusPharma, 101057430, T.N., N.K.), under the Marie S.
180 Curie Grant Agreement (CHAIR, No 860762, S.G., D.T.G., T.N.), the ERC CoG grant for T.N.
181 (FlowHAT, No. 101044355, T.N., M.A.) and FETopen (FLIX, No. 862179, F.R., T.N.).

182 **Keywords:** late-stage diversification • photocatalysis • flow chemistry • unnatural amino acids
183 • peptides.

184

185 **References**

186

187 [1] a) L. Wang, N. Wang, W. Zhang, X. Cheng, Z. Yan, G. Shao, X. Wang, R. Wang, C. Fu,
188 *Signal Transduct. Target. Ther.* **2022**, *7*; b) M. Muttenthaler, G. F. King, D. J. Adams, P. F.
189 Alewood, *Nat. Rev. Drug. Discov.* **2021**, *20*, 309-325; c) E. Valeur, S. M. Guéret, H. Adihou, R.
190 Gopalakrishnan, M. Lemurell, H. Waldmann, T. N. Grossmann, A. T. Plowright, *Angew. Chem.*
191 *Int. Ed.* **2017**, *56*, 10294-10323.

192 [2] a) L. Guillemard, N. Kaplaneris, L. Ackermann, M. J. Johansson, *Nat. Rev. Chem.* **2021**,
193 *5*, 522-545; b) L. Zhang, T. Ritter, *J. Am. Chem. Soc.* **2022**, *144*, 2399-2414; c) P. Bellotti, H.-
194 M. Huang, T. Faber, F. Glorius, *Chem. Rev.* **2023**, *123*, 4237-4352; d) N. J. Castellino, A. P.
195 Montgomery, J. J. Danon, M. Kassiou, *Chem. Rev.* **2023**, *123*, 8127-8153.

196 [3] a) M. A. T. Blaskovich, *J. Med. Chem.* **2016**, *59*, 10807-10836; b) E. Lenci, A.
197 Trabocchi, *Chem. Soc. Rev.* **2020**, *49*, 3262-3277.

198 [4] E. A. Hoyt, P. M. S. D. Cal, B. L. Oliveira, G. J. L. Bernardes, *Nat. Rev. Chem.* **2019**, *3*,
199 147-171.

200 [5] a) M. Jbara, S. K. Maity, A. Brik, *Angew. Chem. Int. Ed.* **2017**, *56*, 10644-10655; b) J.
201 Wang, H. Lundberg, S. Asai, P. Martín-Acosta, J. S. Chen, S. Brown, W. Farrell, R. G. Dushin,
202 C. J. O'Donnell, A. S. Ratnayake, P. Richardson, Z. Liu, T. Qin, D. G. Blackmond, P. S. Baran,
203 *Proc. Natl. Acad. Sci.* **2018**, *115*, E6404-E6410; c) W. Wang, M. M. Lorion, J. Shah, A. R.
204 Kapdi, L. Ackermann, *Angew. Chem. Int. Ed.* **2018**, *57*, 14700-14717; d) J. Ohata, S. C. Martin,
205 Z. T. Ball, *Angew. Chem. Int. Ed.* **2019**, *58*, 6176-6199; e) C. Zhang, E. V. Vinogradova, A. M.

206 Spokoyny, S. L. Buchwald, B. L. Pentelute, *Angew. Chem. Int. Ed.* **2019**, *58*, 4810-4839; f) H.-
207 R. Tong, B. Li, G. Li, G. He, G. Chen, *CCS Chem.* **2021**, *3*, 1797-1820.

208 [6] a) M. Bernús, D. Mazzarella, J. Stanić, Z. Zhai, A. Yeste-Vázquez, O. Boutureira, A. F.
209 G. Gargano, T. N. Grossmann, T. Noël, *Nat. Synth.* **2023**, DOI: 10.1038/s44160-44023-00441-
210 44160; b) L. Markey, S. Giordani, E. M. Scanlan, *J. Org. Chem.* **2013**, *78*, 4270-4277.

211 [7] a) C. Bottecchia, T. Noël, *Chem. Eur. J.* **2019**, *25*, 26-42; b) J.-Q. Liu, A. Shatskiy, B. S.
212 Matsuura, M. D. Kärkäs, *Synthesis* **2019**, *51*, 2759-2791; c) L. Raynal, N. C. Rose, J. R. Donald,
213 C. D. Spicer, *Chem. Eur. J.* **2021**, *27*, 69-88; d) V. M. Lechner, M. Nappi, P. J. Deneny, S. Folliet,
214 J. C. K. Chu, M. J. Gaunt, *Chem. Rev.* **2022**, *122*, 1752-1829.

215 [8] A. S. Mackay, R. J. Payne, L. R. Malins, *J. Am. Chem. Soc.* **2022**, *144*, 23-41.

216 [9] F. J. Aguilar Troyano, K. Merckens, K. Anwar, A. Gómez - Suárez, *Angew. Chem. Int.*
217 *Ed.* **2021**, *60*, 1098-1115.

218 [10] a) E. L. Tyson, Z. L. Niemeyer, T. P. Yoon, *J. Org. Chem.* **2014**, *79*, 1427-1436; b) A.
219 Talla, B. Driessen, N. J. W. Straathof, L. G. Milroy, L. Brunsveld, V. Hessel, T. Noël, *Adv. Synth.*
220 *Catal.* **2015**, *357*, 2180-2186; c) C. Bottecchia, M. Rubens, S. B. Gunnoo, V. Hessel, A. Maddar,
221 T. Noël, *Angew. Chem. Int. Ed.* **2017**, *56*, 12702-12707; d) B. A. Vara, X. Li, S. Berritt, C. R.
222 Walters, E. J. Petersson, G. A. Molander, *Chem. Sci.* **2018**, *9*, 336-344; e) H. Choi, M. Kim, J.
223 Jang, S. Hong, *Angew. Chem. Int. Ed.* **2020**, *59*, 22514-22522; f) R. C. Griffiths, F. R. Smith,
224 D. Li, J. Wyatt, D. M. Rogers, J. E. Long, L. M. L. Cusin, P. J. Tighe, R. Layfield, J. D. Hirst,
225 M. M. Müller, N. J. Mitchell, *Chem. Eur. J.* **2023**, *29*, e202202503.

226 [11] a) Y. Wang, J. Wang, G.-X. Li, G. He, G. Chen, *Org. Lett.* **2017**, *19*, 1442-1445; b) Y.
227 Yu, L.-K. Zhang, A. V. Buevich, G. Li, H. Tang, P. Vachal, S. L. Colletti, Z.-C. Shi, *J. Am.*
228 *Chem. Soc.* **2018**, *140*, 6797-6800; c) B. Ding, Y. Weng, Y. Liu, C. Song, L. Yin, J. Yuan, Y.
229 Ren, A. Lei, C. W. Chiang, *Eur. J. Org. Chem.* **2019**, 7596-7605; d) S. J. Tower, W. J. Hetcher,

230 T. E. Myers, N. J. Kuehl, M. T. Taylor, *J. Am. Chem. Soc.* **2020**, *142*, 9112-9118; e) B. Laroche,
231 X. Tang, G. Archer, R. Di Sanza, P. Melchiorre, *Org. Lett.* **2021**, *23*, 285-289; f) R. N. Lima, J.
232 A. C. Delgado, D. I. Bernardi, R. G. S. Berlinck, N. Kaplaneris, L. Ackermann, M. W. Paixão,
233 *Chem. Commun.* **2021**, *57*, 5758-5761; g) C. R. Hoopes, F. J. Garcia, A. M. Sarkar, N. J. Kuehl,
234 D. T. Barkan, N. L. Collins, G. E. Meister, T. R. Bramhall, C.-H. Hsu, M. D. Jones, M. Schirle,
235 M. T. Taylor, *J. Am. Chem. Soc.* **2022**, *144*, 6227-6236.

236 [12] a) M. T. Taylor, J. E. Nelson, M. G. Suero, M. J. Gaunt, *Nature* **2018**, *562*, 563-568; b)
237 J. Kim, B. X. Li, R. Y.-C. Huang, J. X. Qiao, W. R. Ewing, D. W. C. Macmillan, *J. Am. Chem.*
238 *Soc.* **2020**, *142*, 21260-21266; c) O. J. Knowles, L. O. Johannissen, G. E. M. Crisenza, S. Hay,
239 D. Leys, D. J. Procter, *Angew. Chem. Int. Ed.* **2022**, *61*, e202212158.

240 [13] a) S. Sato, H. Nakamura, *Angew. Chem. Int. Ed.* **2013**, *52*, 8681-8684; b) N. Ichiishi, J.
241 P. Caldwell, M. Lin, W. Zhong, X. Zhu, E. Streckfuss, H.-Y. Kim, C. A. Parish, S. W. Krska,
242 *Chem. Sci.* **2018**, *9*, 4168-4175; c) B. X. Li, D. K. Kim, S. Bloom, R. Y.-C. Huang, J. X. Qiao,
243 W. R. Ewing, D. G. Oblinsky, G. D. Scholes, D. W. C. Macmillan, *Nat. Chem.* **2021**, *13*, 902-
244 908; d) T. Long, L. Liu, Y. Tao, W. Zhang, J. Quan, J. Zheng, J. D. Hegemann, M. Uesugi, W.
245 Yao, H. Tian, H. Wang, *Angew. Chem. Int. Ed.* **2021**, *60*, 13414-13422.

246 [14] C. Bonauer, T. Walenzyk, B. König, *Synthesis* **2006**, 1-20.

247 [15] J. Dadová, S. R. G. Galan, B. G. Davis, *Curr. Opin. Chem. Biol.* **2018**, *46*, 71-81.

248 [16] X. Peng, K. Xu, Q. Zhang, L. Liu, J. Tan, *Trends Chem.* **2022**, *4*, 643-657.

249 [17] a) A. D. De Bruijn, G. Roelfes, *Chem. Eur. J.* **2018**, *24*, 11314-11318; b) T. Rossolini,
250 J. A. Leitch, R. Grainger, D. J. Dixon, *Org. Lett.* **2018**, *20*, 6794-6798; c) T. Brandhofer, O. G.
251 Mancheño, *ChemCatChem* **2019**, *11*, 3797-3801; d) P. Ji, Y. Zhang, Y. Dong, H. Huang, Y. Wei,
252 W. Wang, *Org. Lett.* **2020**, *22*, 1557-1562; e) J. A. Leitch, T. Rossolini, T. Rogova, D. J. Dixon,
253 *ACS Catal.* **2020**, *10*, 11430-11437; f) D. Reich, A. Trowbridge, M. J. Gaunt, *Angew. Chem.*

254 *Int. Ed.* **2020**, *59*, 2256-2261; g) R. C. W. Van Lier, A. D. De Bruijn, G. Roelfes, *Chem. Eur. J.*
255 **2021**, *27*, 1430-1437.

256 [18] B. Josephson, C. Fehl, P. G. Isenegger, S. Nadal, T. H. Wright, A. W. J. Poh, B. J. Bower,
257 A. M. Giltrap, L. Chen, C. Batchelor-Mcauley, G. Roper, O. Arisa, J. B. I. Sap, A. Kawamura,
258 A. J. Baldwin, S. Mohammed, R. G. Compton, V. Gouverneur, B. G. Davis, *Nature* **2020**, *585*,
259 530-537.

260 [19] X. Wang, Y. Chen, H. Song, Y. Liu, Q. Wang, *Org. Lett.* **2021**, *23*, 2199-2204.

261 [20] a) R. A. Aycock, D. B. Vogt, N. T. Jui, *Chem. Sci.* **2017**, *8*, 7998-8003; b) T. Constantin,
262 M. Zanini, A. Regni, N. S. Sheikh, F. Juliá, D. Leonori, *Science* **2020**, *367*, 1021-1026; c) J. R.
263 Immel, M. Chilamari, S. Bloom, *Chem. Sci.* **2021**, *12*, 10083-10091; d) J. R. Immel, S. Bloom,
264 *Angew. Chem. Int. Ed.* **2022**, *61*, e202205606

265 [21] F. Berger, M. B. Plutschack, J. Riegger, W. Yu, S. Speicher, M. Ho, N. Frank, T. Ritter,
266 *Nature* **2019**, *567*, 223-228.

267 [22] M. H. Aukland, M. Šiaučiusis, A. West, G. J. P. Perry, D. J. Procter, *Nat. Catal.* **2020**, *3*,
268 163-169.

269 [23] K. Kafuta, A. Korzun, M. Böhm, C. Golz, M. Alcarazo, *Angew. Chem. Int. Ed.* **2020**,
270 *59*, 1950-1955.

271 [24] H. Meng, M.-S. Liu, W. Shu, *Chem. Sci.* **2022**, *13*, 13690-13707.

272 [25] a) E. M. Alvarez, M. B. Plutschack, F. Berger, T. Ritter, *Org. Lett.* **2020**, *22*, 4593-4596;
273 b) Y. Wu, Y.-H. Huang, X.-Y. Chen, P. Wang, *Org. Lett.* **2020**, *22*, 6657-6661; c) B. Lansbergen,
274 P. Granatino, T. Ritter, *J. Am. Chem. Soc.* **2021**, *143*, 7909-7914; d) D. Zhao, R. Petzold, J. Yan,
275 D. Muri, T. Ritter, *Nature* **2021**, *600*, 444-449; e) M. Wang, X. Zhang, M. Ma, B. Zhao, *Org.*
276 *Lett.* **2022**, *24*, 6031-6036; f) N. Kaplaneris, A. Puet, F. Kallert, J. Pöhlmann, L. Ackermann,
277 *Angew. Chem. Int. Ed.* **2023**, *62*, e202216661.

278 [26] a) R. Sang, S. E. Korkis, W. Su, F. Ye, P. S. Engl, F. Berger, T. Ritter, *Angew. Chem. Int.*
279 *Ed.* **2019**, *58*, 16161-16166; b) F. Ye, F. Berger, H. Jia, J. Ford, A. Wortman, J. Börgel, C.
280 Genicot, T. Ritter, *Angew. Chem. Int. Ed.* **2019**, *58*, 14615-14619; c) J. Li, J. Chen, R. Sang, W.-
281 S. Ham, M. B. Plutschack, F. Berger, S. Chhabra, A. Schnegg, C. Genicot, T. Ritter, *Nat. Chem.*
282 **2020**, *12*, 56-62; d) Y.-L. Zhang, G.-H. Wang, Y. Wu, C.-Y. Zhu, P. Wang, *Org. Lett.* **2021**, *23*,
283 8522-8526; e) M. J. Cabrera - Afonso, A. Granados, G. A. Molander, *Angew. Chem. Int. Ed.*
284 **2022**, *61*, e202202706; f) A. Granados, M. J. Cabrera-Afonso, M. Escolano, S. O. Badir, G. A.
285 Molander, *Chem Catal.* **2022**, *2*, 898-907; g) F.-S. He, P. Bao, Z. Tang, F. Yu, W.-P. Deng, J.
286 Wu, *Org. Lett.* **2022**, *24*, 2955-2960; h) Y. Cai, S. Chatterjee, T. Ritter, *J. Am. Chem. Soc.* **2023**,
287 *145*, 13542-13548; i) W. Zhang, T. Liu, H. T. Ang, P. Luo, Z. Lei, X. Luo, M. J. Koh, J. Wu,
288 *Angew. Chem. Int. Ed.* **2023**, e202310978.

289 [27] a) M.-S. Liu, H.-W. Du, H. Meng, Y. Xie, W. Shu, *Nat. Commun.* **2024**, *15*, 529; b) M.
290 J. Kim, D. J. Wang, K. Targos, U. A. Garcia, A. F. Harris, I. A. Guzei, Z. K. Wickens, *Angew.*
291 *Chem. Int. Ed.* **2023**, *62*, e202303032; c) D. E. Holst, C. Dorval, C. K. Winter, I. A. Guzei, Z.
292 K. Wickens, *J. Am. Chem. Soc.* **2023**, *145*, 8299–8307; d) M. S. Liu, H. W. Du, J. F. Cui, W.
293 Shu, *Angew. Chem. Int. Ed.* **2022**, *61*, e202209929; e) M.-S. Liu, H.-W. Du, W. Shu, *Chem. Sci.*
294 **2022**, *13*, 1003-1008; f) F. Juliá, J. Yan, F. Paulus, T. Ritter, *J. Am. Chem. Soc.* **2021**, *143*, 12992-
295 12998.

296 [28] a) L. Buglioni, F. Raymenants, A. Slattery, S. D. A. Zondag, T. Noël, *Chem. Rev.* **2022**,
297 *122*, 2752-2906; b) L. Capaldo, Z. Wen, T. Noël, *Chem. Sci.* **2023**, *14*, 4230-4247; c) S. D. A.
298 Zondag, D. Mazzarella, T. Noël, *Annu. Rev. Chem. Biomol. Eng.* **2023**, *14*, 283-300.

299